Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.38 USD
Change Today -0.26 / -5.60%
Volume 335.9K
ALIM On Other Exchanges
As of 8:10 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

alimera sciences inc (ALIM) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/1/14 - $8.36
52 Week Low
03/26/15 - $4.31
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ALIMERA SCIENCES INC (ALIM)

alimera sciences inc (ALIM) Related Businessweek News

No Related Businessweek News Found

alimera sciences inc (ALIM) Details

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient’s eye to a placement site that uses the eye’s natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis) or to treat DME. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

70 Employees
Last Reported Date: 03/13/15
Founded in 2003

alimera sciences inc (ALIM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $505.7K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $352.8K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $333.4K
Compensation as of Fiscal Year 2013.

alimera sciences inc (ALIM) Key Developments

Alimera Sciences, Inc. - Shareholder/Analyst Call

To discuss the U.S. commercial launch of ILUVIEN

Alimera Sciences, Inc. Auditor Raises 'Going Concern' Doubt

Alimera Sciences, Inc. filed its 10-K on Mar 13, 2015 for the period ending Dec 31, 2014. In this report its auditor, Grant Thornton, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Alimera Sciences, Inc. Announces Resignation of Philip R. Tracy as a Chairman of the Board and as the Chairman of the Nominating and Corporate Governance Committee of the Board

Philip R. Tracy notified the Board of Directors of Alimera Sciences, Inc. that he did not intend to stand for re-election at the Company's 2015 Annual Meeting of Stockholders, and that he would resign as the chairman of the board and as the chairman of the nominating and corporate governance committee of the board, effective as of the close of business on May 6, 2015, to focus on other activities.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALIM:US $4.38 USD -0.26

ALIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALIM.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALIM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALIMERA SCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at